Clinical-grade regulatory T cells: Comparative analysis of large-scale expansion conditions

2017 ◽  
Vol 45 ◽  
pp. 27-35.e1 ◽  
Author(s):  
Sarvari Velaga ◽  
Christina Alter ◽  
Ulrike Dringenberg ◽  
Christina T. Thiesler ◽  
Sandra Kuhs ◽  
...  
Keyword(s):  
T Cells ◽  
Comparative Analysis ◽  
Regulatory T Cells ◽  
Large Scale ◽  
Clinical Grade ◽  
Scale Expansion

GMP validation of large-scale expansion of regulatory T cells from patients affected by liver and kidney failure

Cytotherapy ◽  
2017 ◽  
Vol 19 (5) ◽  
pp. S117
Author(s):  
C. Lavazza ◽  
M. Vigano' ◽  
T. Montemurro ◽  
E. Montelatici ◽  
S. Budelli ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Kidney Failure ◽  
Large Scale ◽  
Liver And Kidney ◽  
Scale Expansion

scholarly journals Generation and Large-Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft-Versus-Host Disease

2011 ◽  
Vol 11 (6) ◽  
pp. 1148-1157 ◽  
Author(s):  
K. L. Hippen ◽  
S. C. Merkel ◽  
D. K. Schirm ◽  
C. Nelson ◽  
N. C. Tennis ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Graft Versus Host Disease ◽  
Large Scale ◽  
Host Disease ◽  
Graft Versus Host ◽  
Scale Expansion

Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene

2008 ◽  
Vol 10 (8) ◽  
pp. 834-846 ◽  
Author(s):  
Maude Guillot-Delost ◽  
Mustapha Cheraï ◽  
Yamina Hamel ◽  
Michelle Rosenzwajg ◽  
Claude Baillou ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Thymidine Kinase ◽  
Suicide Gene ◽  
Clinical Grade

scholarly journals Comparative analysis of FoxP3+ regulatory T cells in the target tissues and blood in chronic graft versus host disease

Leukemia ◽  
2014 ◽  
Vol 28 (10) ◽  
pp. 2016-2027 ◽  
Author(s):  
M M Imanguli ◽  
E W Cowen ◽  
J Rose ◽  
S Dhamala ◽  
W Swaim ◽  
...  
Keyword(s):  
T Cells ◽  
Comparative Analysis ◽  
Regulatory T Cells ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host

Rapid Clinical Scale Isolation of CD25hiCD4+ Regulatory T Cells.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4969-4969
Author(s):  
Claudia Niemand ◽  
Carina Conrads ◽  
Ramona Siemer ◽  
Mario Assenmacher
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Autoimmune Diseases ◽  
Graft Rejection ◽  
Large Scale ◽  
Mononuclear Cells ◽  
Cd4 Cells ◽  
Isolated Cells ◽  
Cd8 Cells ◽  
Promising Therapeutic Approach

Abstract Several publications during the last few years have reported CD25hiCD4+ regulatory T cells (Tregs) to prevent or to reverse disease in different mouse models of experimental autoimmune encephalomyelitis (EAE), colitis, graft rejection and graft-versus-host-disease (GvHD). As mouse and human Tregs share many phenotypical and functional characteristics, Tregs could provide a promising therapeutic approach for various human autoimmune diseases and pathological alloresponses. Here we have shown that Tregs can be isolated from leukapheresis harvests by CD25 enrichment using the CliniMACS technology (n=13). By this procedure we obtained 2.32x108 (± 1.12x108, range 0.71–4.42x108) cells out of 1010 mononuclear cells with a mean purity of 52.12% (± 12.11%, range 25.48–66.61%) for CD25hiCD4+ cells. Around 90% of enriched cells were CD25+CD4+. Among contaminating CD4− cells most cells were CD25+ which were further characterized by counterstaining to be mainly CD19+ B cells and a few CD8+, CD56+ or CD123+ cells. It is possible to deplete the CD19+ or CD8+ cells by using CD19 Microbeads or CD8 Microbeads respectively with the CliniMACS Instrument before CD25 enrichment. Combined depletion of different cells, e.g. CD19+ and CD8+ cells is conceivable. Isolated cells were phenotypically and functionally characterized. The majority of the CD25hiCD4+ T cells expressed glucocorticoid-induced tumor necrosis factor receptor (GITR), CD62L and CD45RO. In addition, isolated cells were able to suppress the proliferation and activation of cocultured conventional CD4+ cells after polyclonal stimulation with anti-CD3 antibody. We conclude that the large-scale isolation of CD25hiCD4+ regulatory T cells for clinical applications (e.g. therapy of autoimmune diseases, graft rejection or GvHD) is possible by using the CliniMACS CD25 Reagent and the CliniMACS Instrument.

Sign in / Sign up

Export Citation Format

Share Document